XML 21 R10.htm IDEA: XBRL DOCUMENT v3.26.1
Licensed Rights and Other Intangible Assets
 3 Months Ended
Mar. 31, 2026
Licensed Rights and Other Intangible Assets [Abstract]  
Licensed rights and other intangible assets

4. Licensed rights and other intangible assets

 

The following provides information about our license rights and other intangible assets, net as of March 31, 2026 and December 31, 2025 (in thousands):

 

   March 31, 2026   December 31, 2025 
   Gross Carrying
Amount		   Accumulated
Amortization		   Net   Gross Carrying
Amount		   Accumulated
Amortization		   Net 
Intangible assets subject to amortization:                        
Hormone therapy drug patents  $5,695   $2,517   $3,178   $5,695   $2,423   $3,272 
Hormone therapy drug patents applied and pending approval   180    
—
    180    180    
—
    180 
Intangible assets subject to amortization   5,875    2,517    3,358    5,875    2,423    3,452 
Intangible assets not subject to amortization:                              
Trademarks/trade name rights   309    
—
    309    309    
—
    309 
License rights and other intangible assets, net  $6,184   $2,517   $3,667   $6,184   $2,423   $3,761 

  

We recorded in continuing operations amortization expenses related to patents of $94 thousand and $95 thousand for the three months ended March 31, 2026 and 2025, respectively.

 

We conduct regular reviews of our individual patents and patent portfolios. No indicators of impairment were identified, and accordingly, no write-offs were recognized for the three months ended March 31, 2026. In comparison, we recorded write-offs of $88 thousand related to patents pending approval during the three months ended March 31, 2025.

Our intangible assets subject to amortization are expected to be amortized as follows (in thousands):

 

Year ending December 31,
2026  $286 
2027   380 
2028   381 
2029   380 
2030   380 
Thereafter   1,371 
Total  $3,178